Unity Biotechnology, Inc. Quarterly Debt-to-equity in % from Q3 2018 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Unity Biotechnology, Inc. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q2 2024.
  • Unity Biotechnology, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 148 %, a 17.9% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 148 +22.4 +17.9% Jun 30, 2024
Q1 2024 144 +19.4 +15.6% Mar 31, 2024
Q4 2023 133 +6.56 +5.18% Dec 31, 2023
Q3 2023 130 +6.82 +5.55% Sep 30, 2023
Q2 2023 125 +3.79 +3.12% Jun 30, 2023
Q1 2023 125 +11.1 +9.82% Mar 31, 2023
Q4 2022 127 +23.3 +22.6% Dec 31, 2022
Q3 2022 123 +25.3 +25.8% Sep 30, 2022
Q2 2022 121 +33.1 +37.4% Jun 30, 2022
Q1 2022 113 +40.8 +56.1% Mar 31, 2022
Q4 2021 103 +39.2 +61.2% Dec 31, 2021
Q3 2021 97.7 +49.1 +101% Sep 30, 2021
Q2 2021 88.4 +52.5 +147% Jun 30, 2021
Q1 2021 72.6 +43.3 +148% Mar 31, 2021
Q4 2020 64 +44.6 +230% Dec 31, 2020
Q3 2020 48.6 +32.4 +200% Sep 30, 2020
Q2 2020 35.8 +23.3 +185% Jun 30, 2020
Q1 2020 29.3 +20 +215% Mar 31, 2020
Q4 2019 19.4 +4.96 +34.3% Dec 31, 2019
Q3 2019 16.2 -11.6 -41.7% Sep 30, 2019
Q2 2019 12.6 Jun 30, 2019
Q1 2019 9.31 Mar 31, 2019
Q4 2018 14.5 Dec 31, 2018
Q3 2018 27.8 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.